Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $215.88.

ALNY has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price target on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Citigroup lowered their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Chardan Capital reissued a “buy” rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Quent Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $38,000. Robeco Institutional Asset Management B.V. increased its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $52,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 1.3 %

ALNY stock opened at $152.33 on Tuesday. The firm has a 50-day moving average of $149.65 and a two-hundred day moving average of $165.14. The company has a market cap of $19.19 billion, a price-to-earnings ratio of -56.84 and a beta of 0.41. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the company earned ($1.40) EPS. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.